Alnylam: HELIOS-A Phase 3 Study Of Vutrisiran Meets All Secondary Endpoints At 18 Months

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) said the HELIOS-A phase 3 study of vutrisiran met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis

Related Keywords

Washington ,United States ,Rena Denoncourt ,Alnylam Pharmaceuticals Inc , ,Vice President ,Alnylam ,Helios ,Hase ,Study ,Vutrisiran ,Meets ,Secondary ,Endpoints ,Months ,